MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MTR | 5-methyltetrahydrofolate-homocysteine methyltransferase | Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Expressed in all |
MUT | Methylmalonyl CoA mutase | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Expressed in all |
NNMT | Nicotinamide N-methyltransferase | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
NOS3 | Nitric oxide synthase 3 (endothelial cell) | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
PAH | Phenylalanine hydroxylase | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PDE5A | Phosphodiesterase 5A, cGMP-specific | Enzymes FDA approved drug targets
| | | | | Expressed in all |
PDE7A | Phosphodiesterase 7A | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Expressed in all |
PDE8A | Phosphodiesterase 8A | Enzymes FDA approved drug targets
| | | | | Expressed in all |
PDE8B | Phosphodiesterase 8B | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enriched |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
PDXK | Pyridoxal (pyridoxine, vitamin B6) kinase | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
PLA2G1B | Phospholipase A2, group IB (pancreas) | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
PLA2G4A | Phospholipase A2, group IVA (cytosolic, calcium-dependent) | Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Mixed |
PLG | Plasminogen | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PNLIP | Pancreatic lipase | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PNP | Purine nucleoside phosphorylase | Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
POLA1 | Polymerase (DNA directed), alpha 1, catalytic subunit | Enzymes FDA approved drug targets
| | | | | Expressed in all |
POLB | Polymerase (DNA directed), beta | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
POLE | Polymerase (DNA directed), epsilon, catalytic subunit | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
POLE2 | Polymerase (DNA directed), epsilon 2, accessory subunit | Enzymes FDA approved drug targets
| | | | | Mixed |
PRDX5 | Peroxiredoxin 5 | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Expressed in all |
PRKAA1 | Protein kinase, AMP-activated, alpha 1 catalytic subunit | Enzymes FDA approved drug targets
| | | | | Expressed in all |
PROC | Protein C (inactivator of coagulation factors Va and VIIIa) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PSMB1 | Proteasome (prosome, macropain) subunit, beta type, 1 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
PSMB10 | Proteasome (prosome, macropain) subunit, beta type, 10 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
PSMB2 | Proteasome (prosome, macropain) subunit, beta type, 2 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
PSMB5 | Proteasome (prosome, macropain) subunit, beta type, 5 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
PSMB8 | Proteasome (prosome, macropain) subunit, beta type, 8 | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
PSMB9 | Proteasome (prosome, macropain) subunit, beta type, 9 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
PTGS1 | Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
QPRT | Quinolinate phosphoribosyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
REN | Renin | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
RET | Ret proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
RFK | Riboflavin kinase | Enzymes FDA approved drug targets
| | | | | Expressed in all |
RRM1 | Ribonucleotide reductase M1 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
RRM2 | Ribonucleotide reductase M2 | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
RRM2B | Ribonucleotide reductase M2 B (TP53 inducible) | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
SHMT1 | Serine hydroxymethyltransferase 1 (soluble) | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
SI | Sucrase-isomaltase (alpha-glucosidase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
SMOX | Spermine oxidase | Enzymes FDA approved drug targets
| | | | | Expressed in all |
SMS | Spermine synthase | Disease related genes Enzymes FDA approved drug targets
| | | | | Expressed in all |
SOAT1 | Sterol O-acyltransferase 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SRC | V-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Mixed |
TBXAS1 | Thromboxane A synthase 1 (platelet) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
TH | Tyrosine hydroxylase | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enriched |
TOP1 | Topoisomerase (DNA) I | Cancer-related genes Disease related genes Enzymes FDA approved drug targets
| | | | | Expressed in all |
TOP1MT | Topoisomerase (DNA) I, mitochondrial | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Expressed in all |